FDA Oncology Announcements

ALK inhibitor × Thoracic × Clear all

13 Announcements

FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer

Drug: Ensacove (ensartinib) · ALK inhibitor
Condition: Thoracic

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer

Drug: Alecensa (alectinib) · ALK inhibitor
Condition: Thoracic

FDA approves lorlatinib for metastatic ALK-positive NSCLC

Drug: Lorbrena (lorlatinib) · ALK inhibitor
Condition: Thoracic

FDA approves brigatinib for ALK-positive metastatic NSCLC

Trial: ALTA-1L
Drug: ALUNBRIG (brigatinib) · ALK inhibitor
Condition: Thoracic

FDA approves brigatinib for ALK-positive metastatic NSCLC

Trial: ALTA-1L
Drug: ALUNBRIG (brigatinib) · ALK inhibitor
Condition: Thoracic

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

Drug: LORBRENA (lorlatinib) · ALK inhibitor
Condition: Thoracic

Alectinib approved for (ALK) positive metastatic non-small cell lung cancer (NSCLC)

Trial: ALEX
Drug: ALECENSA (alectinib) · ALK inhibitor
Condition: Thoracic

FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC

Drug: ZYKADIA (ceritinib) · ALK inhibitor
Condition: Thoracic

FDA Approves Crizotinib Capsules

Drug: Xalkori (crizotinib) · ALK inhibitor
Condition: Thoracic

Alectinib

Drug: ALECENSA capsules (alectinib) · ALK inhibitor
Condition: Thoracic

FDA Approves Ceritinib

Drug: ZYKADIA (ceritinib) · ALK inhibitor
Condition: Thoracic

FDA Approves Crizotinib

Drug: Xalkori (crizotinib) · ALK inhibitor
Condition: Thoracic

Crizotinib

Drug: XALKORI Capsules (crizotinib) · ALK inhibitor
Condition: Thoracic